The company plans to use proceeds to advance its lead AR-V7 test with Genomic Health, accelerate other assays in its pipeline, and enhance its technology.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The researchers traced the expression of related genes to neural tissues and noted a link between puberty timing and cancer risk.
Qiagen will commercialize its research-use-only AdnaTest to detect AR-V7 from liquid biopsies to investigate resistance to drugs for advanced prostate cancer.
The company awaits a decision from Medicare contractor Novitas, which issued a positive LCD in 2016 but withdrew it in response to a negative LCD from Palmetto.
The company said the revenue increase was driven by strong growth in its ConfirmMDx prostate cancer test and the launch of its SelectMDx liquid biopsy test.
The company beat the consensus Wall Street estimate for the fourth quarter on the bottom line but missed the estimate on the top line.
The company expects Medicare coverage for its test to extend to intermediate prostate cancer patients this year, and it believes new data will help drive increased adoption.
The company published a new study of average- and high-risk patients showing that the test better predicted metastasis in patients treated with radiation and hormonal therapy.
GenomeDx will use its Decipher Classifier and Genomics Resource Information Database to analyze samples, for tumor aggressiveness, and identify predictive signatures.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.